Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience - 03/04/19
, Gioacchino Angarano b , Massimo Colombo c , Antonio Craxì d , Vito Di Marco d , Giovanni Di Perri e , Giovanni Battista Gaeta f , Giuseppe Ippolito g , Alessandra Mangia h , Patrizio Pasqualetti i Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
| páginas | 11 |
| Iconografías | 7 |
| Vídeos | 0 |
| Otros | 0 |
Highlights |
• | Italian Health Authorities instigated programs to eradicate HCV in 2017. |
• | Delphi study identified, improved patient referral, increased role of GPs, greater capacity in Clinical Centers, improved management of high-risk groups and liaison between healthcare professionals, as priorities to meet targets. |
Abstract |
Aims |
In 2017 the Italian Drug Agency (Agenzia Italiana del Farmaco, AIFA) revised the criteria for access to therapy for patients with chronic hepatitis C as part of a three-year plan to eradicate HCV. We conducted a Delphi study to determine strategies to identify and treat patients with HCV and to develop through a shared pathway, a model to manage patient referral and optimize prescription center capacity with the overall aim of increasing access to therapy.
Methods |
The process took place in two phases – Phase I (January 2017), before the criteria for treatment of HCV were revised and Phase II (May 2017) when AIFA developed a framework for the eradication of HCV infection in Italy. Two questionnaires were devised with Q1 administered in Phase I and Q2 in Phase II.
Results |
Q1 was sent to 823 hepatitis specialists working in 235 Italian HCV centers authorized to prescribe direct-acting antiviral drugs (DAAs). Overall, 167 centers (71%) participated with a good geographical representativeness (North 69%, Centre 74%; South and islands 70%). 548 prescribers (68.8%) provided responses to Q1 and 443 (80%) specialists who responded to Q1 completed Q2. Over 70% considered that to meet the new therapy targets local/regional networks need to be consolidated and reinforced with GPs providing the ‘missing link’ in current regional networks. Adherence to therapy was considered important by 75% of clinicians with reduction in follow-up intervals/length considered important by 65% – to free up staff/resources to manage increasing numbers of new patients. About 80% of respondents stated that medical personnel were principally involved in follow-up with follow-up having a significant impact on center capacity.
Conclusion |
Enhancing patient referral, the need for an increased role of GPs, increasing center capacity in particular medical personnel in outpatient centers and greater liaison between Hub centers and healthcare professionals currently managing high-risk groups as yet untreated, were factors that need to be streamlined in order to meet treatment targets for eradication of HCV.
El texto completo de este artículo está disponible en PDF.Keywords : Hepatitis C virus, direct-acting antivirals, Delphi method, disease eradication
Esquema
Vol 43 - N° 2
P. 190-200 - avril 2019 Regresar al número
Artículo precedente
- Analysis of clinical characteristics and S gene sequences in chronic asymptomatic HBV carriers with low-level HBsAg
- Tong Wang, Dawei Cui, Shaoming Chen, Xujian Xu, Changgui Sun, Yuzhu Dai, Jun Cheng
- Risk of metachronous advanced lesions after resection of diminutive and small, non-advanced adenomas
- Ido Laish, Ilia Sergeev, Assaf Stein, Timna Naftali, Fred M. Konikoff
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?